Upcoming Events
Priavoid attends the AD/PD 2026 in Copenhagen between March 17 and 21. During the conference, Priavoid will be having an oral presentation and five poster presentations. Please find the full details on all presentations below:
Oral Presentation:
Abstract Title: The Abeta Oligomer Disassembling Compound PRI-002 Does Not Cause ARIA in an Ongoing Phase 2 Trial (ID 2426)
Presenting author: Prof. Dr. Dieter Willbold, Priavoid GmbH
Date: March 17, 2026
Time: 3:15 PM CET / 9:15 AM EST
Abstract number: TBD
Posters: Posters will be presented in one of the two shifts
Shift 1: Tuesday, March 17, from 7:30 AM till Thursday, March 19, 11:10 AM CET
Abstract Title: #1803: Primus-AD: Design of the Phase 2 Study Treating Early AD Patients with the Novel Drug Candidate PRI-002
Presenting author: Dr. Dagmar Jürgens, Priavoid GmbH
Poster board number: SHIFT 01-323
Shift 2: Thursday, March 19, 1:50 PM till Saturday, March 21, 5:00 PM CET
Abstract Title: #514: Disassembly of α-Synuclein Aggregates by the All-D-Peptide PRI-101: Preclinical Efficacy In Vitro and In Vivo
Presenting author: Dr. Marc Sevenich, Priavoid GmbH
Poster board number: SHIFT 02-152
Abstract Title: #1265: The Aβ Targeting Compound PRI-002 Reduces Aβ Oligomers and Prevents Cognitive Decline in Various AD Animal Models
Presenting author: Dr. Sarah Schemmert, Priavoid GmbH
Poster board number: SHIFT 02-295
Abstract Title: #1621: Development of All-D-Peptides for the Disassembly of Toxic Tau Aggregates
Presenting author: Dr. Nadine Rösener, Priavoid GmbH
Poster board number: SHIFT 02-671
Abstract Title: #1619: Development of Therapeutic Compounds for the Disassembly of TDP-43 Aggregates as a Disease-Modifying Treatment for ALS and FTLD
Presenting author: Dr. Pauline Philippen, Priavoid GmbH
Poster board number: SHIFT 02-695
About Priavoid
Priavoid’s novel class of orally available all-D-peptide therapeutics detangle neurotoxic oligomer species to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders. We aim to establish clinical proof-of-concept through our lead program, PRI-002, which will complete a Phase 2 trial in Alzheimer’s disease in 2026. Priavoid has built a focused pipeline of detangler compounds that are non-immunogenic and reach their oligomer targets in the brain and inside the affected cells. Our goal is to develop disease-modifying therapies that address the underlying biology of neurodegeneration and drive meaningful clinical benefit for patients.